根据最新的财务报表(Form-10K),Virax Biolabs Group Ltd 的总资产为 $0,净亏损为 $0
VRAX 的关键财务比率是什么?
Virax Biolabs Group Ltd 的流动比率是 0,净利 margin 为 0,每股销售为 $0。
Virax Biolabs Group Ltd 的收入按细分市场或地理位置如何划分?
Virax Biolabs Group Ltd 最大收入来源是 ViraxClear and ViraxVet,在最近的收益报告中收入为 156,419。就地区而言, United Kingdom, Hong Kong, Singapore, China, British Virgin Islands 是 Virax Biolabs Group Ltd 的主要市场,收入为 156,419。
Virax Biolabs Group Ltd 是否盈利?
否,根据最新的财务报表,Virax Biolabs Group Ltd 的净亏损为 $0
Virax Biolabs Group Ltd 有负债吗?
否,Virax Biolabs Group Ltd 的负债为 0
Virax Biolabs Group Ltd 的流通股有多少?
Virax Biolabs Group Ltd 的总流通股为 0
关键数据
前收盘价
$2.74
开盘价
$2.7
当日区间
$2.68 - $3.13
52周范围
$0.1 - $3.13
交易量
253.6K
平均成交量
21.5M
股息收益率
--
每股收益(TTM)
-1.25
市值
$62.3M
什么是 VRAX?
Virax Biolabs Group Ltd. is a holding company, which engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The firm is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The firm is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).